

according to the Hazardous Products Regulations

# Atinvicitinib Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 08/14/2024
3.4	09/28/2024	6047681-00016	Date of first issue: 06/19/2020

### **SECTION 1. IDENTIFICATION**

Product name	:	Atinvicitinib Formulation
Other means of identification	:	No data available

#### Manufacturer or supplier's details

Company name of supplier	:	Merck & Co., Inc
Address	:	126 E. Lincoln Avenue
		Rahway, New Jersey U.S.A. 07065
Telephone	:	908-740-4000
Emergency telephone	:	1-908-423-6000
E-mail address	:	EHSDATASTEWARD@merck.com

## Recommended use of the chemical and restrictions on use

Recommended use	:	Veterinary product
Restrictions on use	:	Not applicable

#### **SECTION 2. HAZARDS IDENTIFICATION**

#### GHS classification in accordance with the Hazardous Products Regulations

Not a hazardous substance or mixture.

#### **GHS** label elements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

#### Other hazards

Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin. May form explosive dust-air mixture during processing, handling or other means.

### SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture	:	Mixture

## Components

Chemical name	Common Name/Synonym	CAS-No.	Concentration (% w/w)
Cellulose	No data availa- ble	9004-34-6	54.17
atinvicitinib	No data availa- ble	2169273-59-8	3

### **SECTION 4. FIRST AID MEASURES**

General advice	: In the case of accident or if you feel unwell, seek medical advice immediately.
	When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air. Get medical attention if symptoms occur.



according to the Hazardous Products Regulations

# Atinvicitinib Formulation

Version 3.4	Revision Date: 09/28/2024	SDS Number: 6047681-00016	Date of last issue: 08/14/2024 Date of first issue: 06/19/2020			
In case of skin contact		: Wash with water and soap. Get medical attention if symptoms occur.				
In case of eye contact		: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.				
If swallowed		: If swallowed, Get medical a	DO NOT induce vomiting. attention if symptoms occur. thoroughly with water.			
Most important symptoms and effects, both acute and			dust can cause mechanical irritation or drying of			
	/ed ection of first-aiders s to physician	: No special pr	with the eyes can lead to mechanical irritation. ecautions are necessary for first aid responders. matically and supportively.			

### SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion prod- ucts	:	Carbon oxides Metal oxides
Specific extinguishing meth- ods	:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	:	Wear self-contained breathing apparatus for firefighting if necessary. Use personal protective equipment.

## SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- tive equipment and emer- gency procedures	:	Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.



according to the Hazardous Products Regulations

# Atinvicitinib Formulation

Version	Revision Date:	SDS Number:		Date of last issue: 08/14/2024
3.4	09/28/2024	6047681-00016		Date of first issue: 06/19/2020
	s and materials for ment and cleaning up	:	container for dispo Avoid dispersal of with compressed a Dust deposits sho surfaces, as these released into the a Local or national r disposal of this ma employed in the cl determine which r Sections 13 and 1	dust in the air (i.e., clearing dust surfaces

## SECTION 7. HANDLING AND STORAGE

Technical measures	:	Static electricity may accumulate and ignite suspended dust causing an explosion.
		Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation Advice on safe handling	:	Use only with adequate ventilation. Do not breathe dust.
Advice on sale nandling	•	Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
		Minimize dust generation and accumulation.
		Keep container closed when not in use.
		Keep away from heat and sources of ignition.
		Take precautionary measures against static discharges.
		Take care to prevent spills, waste and minimize release to the environment.
Conditions for safe storage	:	Keep in properly labeled containers.
		Store in accordance with the particular national regulations.
Materials to avoid	:	Do not store with the following product types: Strong oxidizing agents

## SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m <sup>3</sup>	CA AB OEL
		TWA (Total	10 mg/m <sup>3</sup>	CA BC OEL
		dust)		
		TWA (respir-	3 mg/m <sup>3</sup>	CA BC OEL
		able dust		
		fraction)		
		TWAEV (to-	10 mg/m <sup>3</sup>	CA QC OEL



according to the Hazardous Products Regulations

# **Atinvicitinib Formulation**

sion	Revision Date: 09/28/2024	SDS Number:Date of last issue: 08/14/20246047681-00016Date of first issue: 06/19/2020				
		1		tal dust)		1
				TWA	10 mg/m <sup>3</sup>	ACGIH
atinvio	citinib		2169273-59- 8	TWA	80 ug/m3 (OEB 3)	Internal
			0	Wipe limit	800 ug/100cm2	Internal
Engir	neering measures	:	design and op protect produc Containment to are required to	erated in accord cts, workers, a technologies s o control at so d to uncontrolle levices).	uld be implemented by ordance with GMP prin- and the environment. suitable for controlling c urce and to prevent mi- ed areas (e.g., open-fac	ciples to compounds gration of
Perso	onal protective equip	ment				
Respi	ratory protection	:	exposure ass	essment demo	entilation is not availabl onstrates exposures ou	tside the
	ter type protection	:	Particulates ty	•	se respiratory protectic	n.
Ma	aterial	:	Chemical-resi	stant gloves		
	emarks rotection	:	If the work en mists or aeros Wear a faces	lasses with sid vironment or a sols, wear the hield or other f	de shields or goggles. activity involves dusty c appropriate goggles. full face protection if the o the face with dusts, m	ere is a
Skin a	and body protection	:	Work uniform Additional boo task being per disposable su	dy garments sł rformed (e.g., its) to avoid ex ate degowning	coat. nould be used based u sleevelets, apron, gaur xposed skin surfaces. techniques to remove	ntlets,
Hygie	ne measures	:	If exposure to eye flushing s working place When using d Wash contam The effective engineering c appropriate de industrial hygi	chemical is lik ystems and sa o not eat, drin inated clothing operation of a ontrols, proper egowning and	g before re-use. facility should include i r personal protective ec decontamination proce g, medical surveillance	review of quipment, edures,

## SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Color	:	off-white



according to the Hazardous Products Regulations

# **Atinvicitinib Formulation**

/ersion 8.4	Revision Date: 09/28/2024		S Number: 7681-00016	Date of last issue: 08/14/2024 Date of first issue: 06/19/2020
Odor		:	odorless	
Odor T	hreshold	:	No data available	)
рН		:	No data available	)
Melting	g point/freezing point	:	No data available	)
Initial b range	poiling point and boiling	:	No data available	•
Flash <sub>I</sub>	point	:	Not applicable	
Evapo	ration rate	:	Not applicable	
Flamm	nability (solid, gas)	:	May form explosi handling or other	ve dust-air mixture during processing, means.
Flamm	nability (liquids)	:	Not applicable	
	explosion limit / Upper ability limit	:	No data available	
	explosion limit / Lower ability limit	:	No data available	
Vapor	pressure	:	Not applicable	
Relativ	ve vapor density	:	Not applicable	
Relativ	ve density	:	No data available	9
Densit	у	:	0.2 - 0.9 g/cm <sup>3</sup>	
	lity(ies) ter solubility	:	No data available	)
	on coefficient: n- I/water	:	Not applicable	
	nition temperature	:	No data available	)
Decom	nposition temperature	:	No data available	
Viscos Vis	ity cosity, kinematic	:	Not applicable	
Explos	ive properties	:	Not explosive	
Oxidizi	ing properties	:	The substance of	r mixture is not classified as oxidizing.
Molecu	ular weight	:	No data available	9



according to the Hazardous Products Regulations

# **Atinvicitinib Formulation**

Version 3.4	Revision Date: 09/28/2024		S Number: 47681-00016	Date of last issue: 08/14/2024 Date of first issue: 06/19/2020	
Particle	e size	:	No data availa	ble	
SECTION 1	0. STABILITY AND RI	EAC	ΤΙVΙΤΥ		
	vity cal stability ility of hazardous reac-	:	Stable under r May form expl handling or oth	as a reactivity hazard. formal conditions. osive dust-air mixture during processing, fier means. strong oxidizing agents.	
Incomp	ions to avoid patible materials lous decomposition ts	: : :	<b>0 0</b>		

## SECTION 11. TOXICOLOGICAL INFORMATION

#### Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

#### Acute toxicity

Not classified based on available information.

#### Components:

Cellulose.		
Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 5.8 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg
atinvicitinib:		
Acute oral toxicity	:	Assessment: The substance or mixture has no acute oral tox- icity
		LD50 (Rat): > 2,000 mg/kg Assessment: The substance or mixture has no acute oral tox- icity
Acute dermal toxicity	:	LD50 Dermal (Rat, male): > 2,000 mg/kg Assessment: The substance or mixture has no acute dermal toxicity

#### Skin corrosion/irritation

Not classified based on available information.



according to the Hazardous Products Regulations

# Atinvicitinib Formulation

Version         Revision Date:         SDS Number:           3.4         09/28/2024         6047681-00016	Date of last issue: 08/14/2024 Date of first issue: 06/19/2020
---	---

## Components:

#### atinvicitinib:

Species	: human skin
Method	: in vitro skin corrosion test
Result	: No skin irritation

#### Serious eye damage/eye irritation

Not classified based on available information.

#### **Components:**

#### atinvicitinib:

:	Bovine cornea
:	No eye irritation
:	in vitro eye irritation test
:	No eye irritation
	:

#### Respiratory or skin sensitization

### Skin sensitization

Not classified based on available information.

#### **Respiratory sensitization**

Not classified based on available information.

### Components:

#### atinvicitinib:

Test Type	:	Local lymph node assay (LLNA)
Routes of exposure	:	Dermal
Species	:	Mouse
Result	:	Not a skin sensitizer.

### Germ cell mutagenicity

Not classified based on available information.

#### Components:

## Cellulose:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: In vitro mammalian cell gene mutation test Result: negative
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Ingestion Result: negative

#### atinvicitinib:



according to the Hazardous Products Regulations

# **Atinvicitinib Formulation**

ersion 4	Revision Date: 09/28/2024		9S Number: 47681-00016	Date of last issue: 08/14/2024 Date of first issue: 06/19/2020			
Genotoxicity in vitro		:	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative				
			Test Type: Micro Test system: Hu Result: negative	nucleus test nan lymphocytes			
Genotoxicity in vivo		:	: Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Oral Result: negative				
	cell mutagenicity -	:	Weight of eviden cell mutagen.	ce does not support classification as a germ			
Carci	nogenicity						
	assified based on availa	ble	information.				
Comp	oonents:						
Cellu	lose:						
Speci		:	Rat				
	cation Route	÷	Ingestion				
Resul	sure time t	:	72 weeks negative				
	citinib:	_	Not close if a day	a to look of data			
Rema	IFKS	•	Not classified du	e to lack of data.			
•	oductive toxicity assified based on availa	ıble	information.				
Comp	oonents:						
Cellu	lose:						
Effect	s on fertility	:	Test Type: One-s Species: Rat Application Route Result: negative	generation reproduction toxicity study e: Ingestion			
Effect	s on fetal development	:	Test Type: Fertili Species: Rat Application Route Result: negative	ty/early embryonic development e: Ingestion			
	citinib.						
atinvi	Gittinib.						
	s on fertility	:	Remarks: Not cla	assified due to lack of data.			



according to the Hazardous Products Regulations

# **Atinvicitinib Formulation**

exposure based on availat based on availat based on availat base toxicity <u>s:</u> oute	ble i :	Teratogenicity: No Developmental To information.	Maternal: NOAEL: 90
based on availat <b>ed exposure</b> based on availat <b>base toxicity</b> <u> s:</u> oute	ble i :	information.	
based on availat <b>se toxicity</b>	:		
<u>s:</u> oute	:	Rat	
oute	:	Rat	
	:	Rat	
	:	Rat	
	:	>= 9,000 mg/kg Ingestion 90 Days	
oute e :posures			male
oute e :posures	: : : : : : : : : : : : : : : : : : : :	Rat, male and fer 5 mg/kg Oral 3 Months Daily	nale
oute e :posures			nale
	e posures oute e posures oute e posures <b>oxicity</b>	e : posures : oute : e : posures : e : posures : e : posures : based on available i	e : 6 Months posures : Daily : Rat, male and fer : 5 mg/kg oute : Oral e : 3 Months posures : Daily : Rat, male and fer : 12 mg/kg oute : Dermal e : 3 Months posures : Daily <b>based on available information.</b>

atinvicitinib:

Not applicable



according to the Hazardous Products Regulations

# **Atinvicitinib Formulation**

Version 3.4	Revision Date: 09/28/2024		0S Number: 47681-00016	Date of last issue: 08/14/2024 Date of first issue: 06/19/2020
SECTION	12. ECOLOGICAL INFO		ΙΔΤΙΟΝ	
SECTION				
Ecote	oxicity			
Com	ponents:			
Cellu	lose:			
Toxic	ity to fish	:	Exposure time: 48	pes (Japanese medaka)): > 100 mg/l s h on data from similar materials
atinv	icitinib:			
Toxic	ity to fish	:	Exposure time: 96 Method: OECD Te	
	Toxicity to daphnia and other aquatic invertebrates		Exposure time: 48 Method: OECD Te	
			Exposure time: 96 Method: OPPTS 8	
Toxic plants	ity to algae/aquatic s	:	100 mg/l End point: Growth Exposure time: 72 Method: OECD Te	h .
Toxic	ity to microorganisms	:	EC10: > 1,000 mg Exposure time: 3 Test Type: Respir Method: OECD Te	h ation inhibition of activated sludge
			EC50: > 1,000 mg Exposure time: 3 Test Type: Respir Method: OECD Te	h ation inhibition of activated sludge
Ecote	oxicology Assessment			
Acute	e aquatic toxicity	:	No data available	
Chror	nic aquatic toxicity	:	No data available	



according to the Hazardous Products Regulations

# Atinvicitinib Formulation

Vers 3.4	sion	Revision Date: 09/28/2024	SDS Number: 6047681-00016	Date of last issue: 08/14/2024 Date of first issue: 06/19/2020
	Persis	tence and degradabil	ity	
	Comp	onents:		
	Cellulo	ose:		
	Biodeg	radability	: Result: Readily b	iodegradable.
	Bioaco	cumulative potential		
	Comp	onents:		
	<b>atinvic</b> Partitio octano	n coefficient: n-	: log Pow: 1.45	
	Mobilit	ty in soil		
	No dat	a available		
	Other	adverse effects		
	No dat	a available		
SEC	TION 1	3. DISPOSAL CONSI	DERATIONS	

Waste from residues	:	Do not dispose of waste into sewer.
		Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

### **SECTION 14. TRANSPORT INFORMATION**

#### International Regulations

#### UNRTDG

Not regulated as a dangerous good

### IATA-DGR Not regulated as a dangerous good

**IMDG-Code** Not regulated as a dangerous good

## Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

#### **Domestic regulation**

**TDG** Not regulated as a dangerous good

#### Special precautions for user

Not applicable



according to the Hazardous Products Regulations

# Atinvicitinib Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 08/14/2024
3.4	09/28/2024	6047681-00016	Date of first issue: 06/19/2020

#### **SECTION 15. REGULATORY INFORMATION**

The ingredients of this product are reported in the following inventories:						
DSL	:	not determined				
AICS	:	not determined				
IECSC	:	not determined				

### SECTION 16. OTHER INFORMATION

#### Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
CA AB OEL	:	Canada. Alberta, Occupational Health and Safety Code (table 2: OEL)
CA BC OEL	:	Canada. British Columbia OEL
CA QC OEL	:	Québec. Regulation respecting occupational health and safe- ty, Schedule 1, Part 1: Permissible exposure values for air- borne contaminants
ACGIH / TWA	:	8-hour, time-weighted average
CA AB OEL / TWA	:	8-hour Occupational exposure limit
CA BC OEL / TWA	:	8-hour time weighted average
CA QC OEL / TWAEV	:	Time-weighted average exposure value

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System: GLP - Good Laboratory Practice: IARC - International Agency for Research on Cancer: IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transporta-



according to the Hazardous Products Regulations

# Atinvicitinib Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 08/14/2024
3.4	09/28/2024	6047681-00016	Date of first issue: 06/19/2020

tion of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen- cy, http://echa.europa.eu/
Revision Date Date format	:	09/28/2024 mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8